And NBC reports first death in Puerto Rico caused by Zika virus. Oh well, "we can't pass any request that comes from that nasty ole White House!"
Astra Zeneca sold marketing rights of Ardea's gout drug to the GI drug company Ironwood. I guess there isn't a great demand for new gout treatments, and that's why Biocryst dropped 4208.
It's the realization that the Baker Brothers get things wrong too. See the cliff that Catalyst Pharmaceuticals (CPRX) fell off today. BB own 10%. Sudden fear that they may be wrong about Biocryst.
Map, see abstract 42 -
Broad-spectrum Antiviral Activity of GS-5734, a Novel Adenine Nucelotide Analog Prodrug Across the Families Filoviridae and Paramyxoviridae
"Yesterday Rob says data on 4430 will "be discussed" at the ongoing ICAR antiviral conference this week, but no data has come out publicly."
It isn't coming out publicly in a presentation at the ICAR conference this week either, although Gilead has a presentation about its antiviral. MUM's the word. This management is afraid of losing or being sued, and if you're tight-lipped you can't be accused of pumping.
conference presentation from 2012!!!! 3-1/2 years ago. That's ok, we're just taking our time, while yellow fever kills over 200 people in the past month alone.
From the summary - "A Phase 1 clinical trial of intramuscular administration of BCX4430 in healthy subjects is currently ongoing." In vitro tests reveal a pronounced efficacy in filoviruses.
Reading these things make me crazy. 2 years guys, 2 years since the Nature article..
Lysander: I wonder if executives' connections make the difference. DYAX founders and BOD had all the connections you would need to be successful in biotech. Just look at IPO companies that are 1 or 2 yrs old that have been bought out recently for billions. They are in cancer and they have founders with big-time reputations and connections. I guess that Mr. Stonehouse, in spite of his stint with big pharma, is not well known in the big time biotech circuit. That HAE flop did not help his reputation. Add it to the short-needle episode, the inability to fund 4208, dumbfounding 4430 lack of results made public. His status is not high right now. What's in it for the institutions???
If there was any possibility for 4430 for Zika, I think the company would be talking about it by now. Forget about it for now. If it comes, it comes. I listened to an American Chemical Society Webinar on Zika the morning given by 3 experts. No really solid anti-virals available, and 4430 not mentioned.
Lysander - I tried to listen. Apparently, the company profile (see Husky message) was put up by the same people who set up the online presentation. It needs a Microsoft app called Starlight, similar to Adobe. My new Dell pc has a level 6 processor and Windows 10, and yet I received an "incompatible" warning when I tried to download Starlight. No presentation for me. My Biocryst frustration this year goes on.
I last spoke to Rob in Feb. and asked him to clarify the trial dates for me on different docs. He said he would but never got back to me. I called him again and left a message on 4/8. Inquiring minds want to know.
I am going to risk being called who knows what but the date of the trial info that was posted for the BCX4430 studies by Quotient is Nov, 2014, so that the completion date would have been March 2015, NOT March 2016. Sorry guys, but govt or no govt, this yearlong delay does not bode well. HAE is my bet. Forget 4430; fagedaboudid! If it happens, I will be ecstatic. I assure you I'm not short, since my accts are IRAs.
BTW, I think that the extensive credit given to shorts for price control are overstated.
I have been looking regularly at the Quotient Clinical volunteers website for the last 6 months at least and never saw it mentioned. It would have been hard to miss a posting of an antiviral medication. Oh well. Where do you see that it was completed in March?
watching this stock is like golf. trying to hit a little ball into a little hole that is far, far away. frustrating as h**l.
"Looks like the 2nd part of the study started with screen volunteers on the 19th of Feb. and start date of the 25th."
This is not on the Quotient website. Where is this from?
What connects this Quotient study entry to BCX4430? And even if it is, it's a year and a half old. Clinicaltrials.gov hasn't been updated recently.